Jon Heinrichs

Jon Heinrichs leads IAVI’s antibody program strategy and translational immunology function. In this role, he oversees translation of IAVI’s monoclonal antibody development program into clinical evaluation, including our HIV broadly neutralizing antibody program for prevention of HIV acquisition. In the translational immunology area, he partners across the organization to identify and co-develop new and complementary research programs, including using state-of-the-art immunologic methods to delineate correlates of protection for vaccine candidates across our portfolio and to contribute to the evidence base to support licensure.

Heinrichs has had a distinguished career in vaccine R&D, with thirty years of experience at leading biopharmaceutical companies, including Sanofi Pasteur, Merck, and MedImmune (now part of AstraZeneca). Most recently he served as global head of innovation and emerging sciences at Sanofi and led development of the monoclonal antibody nirsevimab (Beyfortus), now licensed for the prevention of RSV disease in infants.

Heinrichs earned his Ph.D. and M.S. in microbiology and molecular genetics from Rutgers University and completed a post-doctoral fellowship in the Laboratory of Bacterial Pathogenesis and Immunology at The Rockefeller University in New York.